Developing high-value therapies often means working with scarce material, fragile formats, and tight margins for error. This white paper explores how small-batch lyophilization enables precise, high-yield manufacturing for early-phase, patient-specific, and solubility-limited products.
Learn how formulation choices, freezing strategies, and equipment design affect recovery, stability, and bioavailability when API is scarce, and losses aren’t an option. OFD Life Sciences applies a development-first model to meet the precision demands of small-batch programs.